Gilead’s Covid drug is mediocre. It will be a blockbuster anyway.

Gilead’s Covid drug is mediocre. It will be a blockbuster anyway. The company said that by December, it expected to have produced enough drug to treat 2 million patients and that it was studying an inhaled form of the drug that could expand its use to outpatients. https://ift.tt/eA8V8J

Comments

Post a Comment

Popular posts from this blog

Women in India Report Higher Sleep Deprivation Than Men

The survey, conducted by Resmed, gathered insights from 30,000 people across 13 countries, including 5,000 respondents in India. The findings highlight a growing recognition of sleep as a health priority and underlined a persistent gaps in achieving consistent, quality rest. from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/14OaF7t via gqrds
Read more

Nadda reviews healthcare delivery mechanisms in Rajasthan, Maharashtra

The discussion centred on reinforcing public health infrastructure, improving patient-centric services, strengthening regulatory frameworks, and advancing India's commitment to eliminating tuberculosis as a public health challenge, the health ministry said in a statement. from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/avQFOIc via gqrds
Read more

ICMR to roll out multi-state study to expand palliative care access

The proposed study aims to develop and test scalable palliative care models across district hospitals, community health centres, primary health centres and home-based settings, covering patients across age groups and illnesses. from Top Health News | Latest Healthcare Sector & Healthcare Industry news, Information and Updates: ET HealthWorld : ETHealthworld.com https://ift.tt/hilCMYn via gqrds
Read more